Results 81 to 90 of about 53,742 (236)

No Association Between Pharmacogenomics Variants and Hospital and Emergency Department Utilization: A Mayo Clinic Biobank Retrospective Study

Pharmacogenomics and Personalized Medicine, 2021
Paul Y Takahashi,1 Euijung Ryu,2 Suzette J Bielinski,3 Matthew Hathcock,2 Gregory D Jenkins,2 James R Cerhan,3 Janet E Olson3 1Division of Community Internal Medicine, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA; 2Division of ...
Takahashi PY, Ryu E, Bielinski SJ, Hathcock M, Jenkins GD, Cerhan JR, Olson JE   +6 more
doaj  

Pharmacogenomics landscape of COVID-19 therapy response in Serbian population and comparison with worldwide populations [PDF]

Journal of Medical Biochemistry, 2020
Background: Since there are no certified therapeutics to treat COVID-19 patients, drug repurposing became important. With lack of time to test individual pharmacogenomics markers, population pharmacogenomics could be helpful in predicting a higher risk ...
Stanković Biljana, Kotur Nikola, Gašić Vladimir, Klaassen Kristel, Ristivojević Bojan, Stojiljković Maja, Pavlović Sonja, Zukić Branka   +7 more
doaj  

The genomics of neonatal abstinence syndrome [PDF]

, 2017
Significant variability has been observed in the development and severity of neonatal abstinence syndrome (NAS) among neonates exposed to prenatal opioids.
Cole, F. Sessions, Davis, Jonathan M, Wegner, Daniel J   +2 more
core   +3 more sources

UGT1A1 and Sacituzumab Govitecan Toxicity: A Systematic Review and Meta‐Analysis

Clinical Pharmacology &Therapeutics, EarlyView.
Sacituzumab govitecan (SG), a humanized antibody‐drug conjugate, enables intra‐tumor delivery of SN‐38, the active metabolite of irinotecan, with the aim of increasing efficacy. SN‐38 is predominantly inactivated by the polymorphically expressed uridine diphosphate glucuronosyltransferase 1A1 (UGT1AA) where reduced activity can lead to toxicity.
Cinzia Dello Russo, Innocent Gerald Asiimwe, Sudeep Pushpakom, Carlo Palmieri, Munir Pirmohamed   +4 more
wiley   +1 more source

Context, ethics and pharmacogenetics [PDF]

, 2006
Most of the literature on pharmacogenetics assumes that the main problems in implementing the technology will be institutional ones (due to funding or regulation) and that although it involves genetic testing, the ethical issues involved in ...
Adam M. Hedgecoe, Akhtar, Anderson, Anon, Bazell, Beauchamp, Beeson, Brodaty, Brushwood, Clarke, DeVries, Emery, Ensom, Evans, Farlow, Farrer, Fox, Ginsburg, Haimes, Haseltine, Hedgecoe, Hedgecoe, Hoffmaster, Hoffmaster, Issa, Issa, Jazwinska, Johnson, Kumar, Kumar, Levine, Lindpaintner, Lindpaintner, McConnell, McLeod, Nelson, Noguchi, Nuffield Council on Bioethics., Palmer, Pfost, Poirier, Post, Relkin, Richard, Rioux, Ritchie, Robertson, Roses, Rothstein, Rusnak, Sadee, Saunders, Shi, Smith, Smith, Sugarman, Vaszar, Wolf, Zussman   +58 more
core   +1 more source

Clinical Pharmacogenetics Implementation Consortium Guideline for NAT2 Genotype and Hydralazine Therapy

Clinical Pharmacology &Therapeutics, EarlyView.
Hydralazine is a vasodilator typically used in the treatment of resistant hypertension and heart failure. N‐acetyltransferase 2 (NAT2) catalyzes the metabolism of hydralazine into inactive metabolites. NAT2 poor metabolizers (historically referred to as “slow acetylators”) are predicted to have increased plasma hydralazine concentrations compared with ...
Michael T. Eadon, David W. Hein, Michael A. Andersen, Arlene B. Chapman, Rhonda M. Cooper‐DeHoff, Zeruesenay Desta, Julio D. Duarte, Amanda L. Elchynski, Andrea Gaedigk, Seth E. Karol, Nita A. Limdi, Christelle Lteif, Laura Sosinski, Pablo Zubiaur, Michelle Whirl‐Carrillo, Teri E. Klein, Kelly E. Caudle, Roseann S. Donnelly, José A.G. Agúndez   +18 more
wiley   +1 more source

DNA methylation at the mu-1 opioid receptor gene (OPRM1) promoter predicts preoperative, acute, and chronic postsurgical pain after spine fusion. [PDF]

, 2017
INTRODUCTION:The perioperative pain experience shows great interindividual variability and is difficult to predict. The mu-1 opioid receptor gene (OPRM1) is known to play an important role in opioid-pain pathways.
Chidambaran, Vidya, Ding, Lili, Geisler, Kristie, Ji, Hong, Martin, Lisa J, Sadhasivam, Senthilkumar, Stubbeman, Bobbie L, Weirauch, Matthew T, Zhang, Xue   +8 more
core   +1 more source

Clinical Implementation of Pharmacogenomics and Drug–Drug Interaction Screening in a German Academic Teaching Hospital and Outpatient Follow‐Up

Clinical Pharmacology &Therapeutics, EarlyView.
Overview of the implemented pharmacogenomics (PGx) process in clinical routine at the Robert Bosch Hospital: from patient enrollment via the hospital information system, DNA detection using a customized TaqMan OpenArray panel and qPCR for CNV assessment, to clinical translation of genotyping results into PGx guideline‐based recommendations using a ...
Roman Tremmel, Filippa Schreeck, Simon Jaeger, Severin Schricker, Elke Schaeffeler, Svitlana Igel, Daniela Steinberger, Manuel Pagitz, Jörg Latus, Markus Ketteler, Kerstin Bühl, Marc‐H. Dahlke, Hans‐Georg Kopp, Matthias Schwab   +13 more
wiley   +1 more source

Profiling and targeting HER2-positive breast cancer using trastuzumab emtansine. [PDF]

, 2014
PurposeThis article reviews the mechanism of action of trastuzumab emtansine (T-DM1), existing clinical data relating to its use for human growth factor receptor 2 (HER2)-positive breast cancer, potential pathways of resistance, and ongoing studies ...
Hurvitz, Sara A, Olevsky, Olga, Sadeghi, Saeed   +2 more
core   +1 more source

Electronic Patient File‐Embedded Model‐Informed Precision Dosing Compared with Physician Dosing of Tacrolimus in Kidney Transplantation

Clinical Pharmacology &Therapeutics, EarlyView.
Model‐informed precision dosing (MIPD) of tacrolimus in renal allograft recipients, evaluated in silico, demonstrated improved (time to and) probability of target concentration attainment and smaller deviations from target range. Using simulated tacrolimus concentration‐time profiles, a study of 200 patients was predicted to have sufficient power to ...
Dirk R.J. Kuypers, Pieter Annaert, Borefore Jallah, Maarten Naesens, Maxine Teuns, Annouschka Laenen, Ruben Faelens   +6 more
wiley   +1 more source